CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nanosphere, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nanosphere, Inc.
4088 Commercial Ave.
Phone: (847) 400-9000p:847 400-9000 Northbrook, IL  60062-1829  United States Fax: (302) 655-5049f:302 655-5049

This company ceased filing statements with the SEC on 7/19/2016.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Nanosphere, Inc. is engaged in developing, manufacturing and marketing an advanced molecular diagnostics platform, the Verigene System, which enables genomic and protein testing on a single platform. The Verigene System includes a molecular diagnostics workstation that is a single use consumable for testing. The Verigene System consists of a microfluidics processor, a touchscreen reader and disposable test cartridges. The Company is focused on the infectious disease diagnostics market. Its Infectious Disease Assays include Respiratory Virus with Sub-Typing (RV+); Respiratory Pathogens/Expanded Panel (RP Flex); Bloodstream Infection (BSI) Panels, which include Blood Culture – Gram Positive (BC-GP), Blood Culture – Gram Negative (BC-GN) and Blood Culture – Yeast (BC-Y); C. difficile (CDF), and Enteric Panel (EP). Its Human Pharmacogenetic Assays include Hypercoagulation (FV, FII, MTHFR Panel) and CYP2C19 Genetic Variance. It is focused on the infectious disease diagnostics market.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/201612/31/2015YesYes--Yes

Industries
SIC Code Description
3841 Surgical and medical instruments and apparatus

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Lorin J.Randall 72 7/1/2015 9/16/2008
President, Chief Executive Officer, Director Michael K.McGarrity 52 2/1/2013 1/1/2005
Acting Principal Financial Officer, Interim Chief Accounting Officer, and Secretary FarzanaMoinuddin 41 6/12/2015 6/12/2015
5 additional Officers and Directors records available in full report.

General Information
Stock Exchange: NASD
Federal Tax Id: 364339870
Fax Number: (302) 655-5049
Email Address: info@nanosphere.us


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023